1.Ong, ACM et al. (2015) Autosomal dominant polycystic kidney disease: the changing face of clinical management. The Lancet 385, 1993–2002.
2.Lanktree, MB et al. (2018) Prevalence estimates of polycystic kidney and liver disease by population sequencing. Journal of the American Society of Nephrology 29, 2593–2600.
3.Rangan, GK et al. (2016) Recent advances in autosomal-dominant polycystic kidney disease. Internal Medicine Journal 46, 883–892.
4.Porath, B et al. (2016) Mutations in GANAB, encoding the glucosidase IIalpha subunit, cause autosomal-dominant polycystic kidney and liver disease. American Journal of Human Genetics 98, 1193–1207.
5.Cornec-Le Gall, E et al. (2018) Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. American Journal of Human Genetics 102, 832–844.
6.Rangan, GK et al. (2015) Autosomal dominant polycystic kidney disease: a path forward. Seminars in Nephrology 35, 524.
7.Chatterjee, S, Verma, SP and Pandey, P (2017) Profiling conserved biological pathways in Autosomal Dominant Polycystic Kidney Disorder (ADPKD) to elucidate key transcriptomic alterations regulating cystogenesis: a cross-species meta-analysis approach. Gene 627, 434–450.
8.Grantham, JJ, Geiser, JL and Evan, AP (1987) Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney International 31, 1145–1152.
9.Grantham, JJ (2008) Autosomal dominant polycystic kidney disease. The New England Journal of Medicine 359, 1477–1485.
10.Bae, KT et al. (2019) Growth pattern of kidney cyst number and volume in autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology 14, 823–833.
11.Lindahl, T and Barnes, DE (2000) Repair of endogenous DNA damage. Cold Spring Harbor Symposia on Quantitative Biology 65, 127–133.
12.Hoeijmakers, JHJ (2009) DNA damage, aging, and cancer. The New England Journal of Medicine 361, 1475–1485.
13.Jackson, SP and Bartek, J (2009) The DNA-damage response in human biology and disease. Nature 461, 1071–1078.
14.Kuo, LJ and Yang, LX (2008) γ-H2AX- A novel biomaker for DNA double-strand breaks. In Vivo 22, 305–310.
15.Jena, NR (2012) DNA damage by reactive species: mechanisms, mutation and repair. Journal of Biosciences 37, 503–517.
16.Lindahl, T (1993) Instability and decay of the primary structure of DNA. Nature 362, 709–715.
17.Friedberg, EC, McDaniel, LD and Schultz, RA (2004) The role of endogenous and exogenous DNA damage and mutagenesis. Current Opinion in Genetics & Development 14, 5–10.
18.De Bont, R and van Larebeke, N (2004) Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis 19, 169–185.
19.Birben, E et al. (2012) Oxidative stress and antioxidant defense. World Allergy Organization Journal 5, 9–19.
20.O'Connor, MJ (2015) Targeting the DNA damage response in cancer. Molecular Cell 60, 547–560.
21.Lord, CJ and Ashworth, A (2012) The DNA damage response and cancer therapy. Nature 481, 287–294.
22.Christensson, A et al. (2013) Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. International Journal of Cancer 133, 1452–1458.
23.Wong, G et al. (2009) Association of CKD and cancer risk in older people. Journal of the American Society of Nephrology 20, 1341–1350.
24.Cengiz, K et al. (1988) Sister chromatid exchange and chromosome abnormalities in uremic patients. Cancer Genetics and Cytogenetics 36, 55–67.
25.Sandoval, SB et al. (2012) Genomic instability in chronic renal failure patients. Environmental and Molecular Mutagenesis 53, 343–349.
26.Sandoval, SB et al. (2010) Genetic damage in chronic renal failure patients is associated with the glomerular filtration rate index. Mutagenesis 25, 603–608.
27.Vamvakas, S et al. (1996) Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immunosuppression after renal transplantation. Transplantation Proceedings 28, 3468–3473.
28.Zevin, D et al. (1991) Impaired DNA repair in patients with end-stage renal disease and its improvement with hemodialysis. Mineral and Electrolyte Metabolism 17, 303–306.
29.Small, DM et al. (2012) Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology 17, 311–321.
30.Sung, C-C et al. (2013) Oxidative stress and nucleic acid oxidation in patients with chronic kidney disease. Oxidative Medicine and Cellular Longevity 2013, 1–15.
31.Akagi, S et al. (2003) Significance of 8-hydroxy-2′-deoxyguanosine levels in patients with chronic renal failure. Nephrology 8, 192–195.
32.Martinez, JR and Grantham, JJ (1995) Polycystic kidney disease: etiology, pathogenesis, and treatment. Disease-a-Month 41, 693–765.
33.Lantinga-van Leeuwen, IS et al. (2004) Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Human Molecular Genetics 13, 3069–3077.
34.Jiang, S-T et al. (2006) Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1. American Journal of Pathology 168, 205–220.
35.Rossetti, S et al. (2009) Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney International 75, 848–855.
36.Hopp, K et al. (2012) Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. Journal of Clinical Investigation 122, 4257–4273.
37.Grantham, JJ, Chapman, AB and Torres, VE (2006) Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clinical Journal of the American Society of Nephrology 1, 148.
38.Calvet, JP (2008) Strategies to inhibit cyst formation in ADPKD. Clinical Journal of the American Society of Nephrology 3, 1205–1211.
39.Harris, PC (2010) What is the role of somatic mutation in autosomal dominant polycystic kidney disease? Journal of the American Society of Nephrology 21, 1073–1076.
40.Qian, F et al. (1996) The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87, 979–987.
41.Brasier, JL and Henske, EP (1997) Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis. Journal of Clinical Investigation 99, 194–199.
42.Wu, G et al. (1998) Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93, 177–188.
43.Watnick, TJ et al. (1998) Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Molecular Cell 2, 247–251.
44.Pei, Y et al. (1999) Somatic PKD2 mutations in individual kidney and liver cysts support a ‘two-hit’ model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. Journal of the American Society of Nephrology 10, 1524–1529.
45.Koptides, M et al. (1999) Germinal and somatic mutations in the PKD2 gene of renal cysts in autosomal dominant polycystic kidney disease. Human Molecular Genetics 8, 509–513.
46.Takakura, A et al. (2008) Pkd1 inactivation induced in adulthood produces focal cystic disease. Journal of the American Society of Nephrology 19, 2351–2363.
47.Tan, AY et al. (2018) Somatic mutations in renal cyst epithelium in autosomal dominant polycystic kidney disease. Journal of the American Society of Nephrology 29, 2139–2156.
48.Takakura, A et al. (2009) Renal injury is a third hit promoting rapid development of adult polycystic kidney disease. Human Molecular Genetics 18, 2523–2531.
49.Leonhard, WN et al. (2015) Scattered deletion of PKD1 in kidneys causes a cystic snowball effect and recapitulates polycystic kidney disease. Journal of the American Society of Nephrology 26, 1322–1333.
50.Kenter, AT et al. (2019) Identifying cystogenic paracrine signaling molecules in cyst fluid of patients with polycystic kidney disease. American Journal of Physiology – Renal Physiology 316, F204–F213.
51.Johnson, CA and Collis, SJ (2016) Ciliogenesis and the DNA damage response: a stressful relationship. Cilia 5, 19.
52.Attanasio, M (2015) Ciliopathies and DNA damage: an emerging nexus. Current Opinion in Nephrology and Hypertension 24, 366–370.
53.Slaats, GG and Giles, RH (2015) Are renal ciliopathies (replication) stressed out? Trends in Cell Biology 25, 317–319.
54.Chaki, M et al. (2012) Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell 150, 533–548.
55.Slaats, GG et al. (2014) Nephronophthisis-associated CEP164 regulates cell cycle progression, apoptosis and epithelial-to-mesenchymal transition. PLoS Genetics 10, e1004594.
56.Torres, VE and Harris, PC (2006) Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nature Clinical Practice Nephrology 2, 40–55.
57.Dmitrieva, NI, Cai, Q and Burg, MB (2004) Cells adapted to high NaCl have many DNA breaks and impaired DNA repair both in cell culture and in vivo. Proceedings of the National Academy of Sciences of the United States of America 101, 2317–2322.
58.Smith, LA et al. (2006) Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. Journal of the American Society of Nephrology 17, 2821–2831.
59.Sohara, E et al. (2008) Nek8 regulates the expression and localization of polycystin-1 and polycystin-2. Journal of the American Society of Nephrology 19, 469–476.
60.Choi, H et al. (2013) NEK8 links the ATR-regulated replication stress response and S phase CDK activity to renal ciliopathies. Molecular Cell 51, 423–439.
61.Airik, R et al. (2014) Renal-retinal ciliopathy gene Sdccag8 regulates DNA damage response signaling. Journal of the American Society of Nephrology 25, 2573–2583.
62.Cassini, MF et al. (2018) Mcp1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease. Journal of the American Society of Nephrology 29, 2471–2481.
63.Ta, MHT et al. (2016) Constitutive renal Rel/nuclear factor-κB expression in Lewis polycystic kidney disease rats. World Journal of Nephrology 5, 339.
64.Lecona, E and Fernández-Capetillo, O (2014) Replication stress and cancer: it takes two to tango. Experimental Cell Research 329, 26–34.
65.Liu, G et al. (2012) Replication fork stalling and checkpoint activation by a PKD1 locus mirror repeat polypurine-polypyrimidine (Pu-Py) tract. The Journal of Biological Chemistry 287, 33412–33423.
66.Lea, WA et al. (2018) Human-specific abnormal alternative splicing of wild-type PKD1 induces premature termination of polycystin-1. Journal of the American Society of Nephrology 29, 2482–2492.
67.Li, M et al. (2013) Genomic instability in patients with autosomal-dominant polycystic kidney disease. Journal of International Medical Research 41, 169–175.
68.Battini, L et al. (2008) Loss of polycystin-1 causes centrosome amplification and genomic instability. Human Molecular Genetics 17, 2819–2833.
69.Yu, T-M et al. (2016) Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study. The Lancet Oncology 17, 1419–1425.
70.Cachat, F and Renella, R (2016) Risk of cancer in patients with polycystic kidney disease. The Lancet Oncology 17, e474.
71.Chapman, JR and Wong, G (2016) Cancer in patients with inherited ciliopathies: polycystic kidney disease. The Lancet Oncology 17, 1343–1345.
72.Wetmore, JB et al. (2014) Polycystic kidney disease and cancer after renal transplantation. Journal of the American Society of Nephrology 25, 2335–2341.
73.Apeland, T, Holdaas, H and Mansoor, MA (2014) Kidney donors and kidney transplants have abnormal aminothiol redox status, and are at increased risk of oxidative stress and reduced redox buffer capacity. Clinical Biochemistry 47, 378–382.
74.Tariq, A et al. (2018) Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy. Clinical Biochemistry 56, 33–40.
75.Nowak, KL et al. (2018) Vascular dysfunction, oxidative stress, and inflammation in autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology 13, 1493–1501.
76.Woo, YM et al. (2014) Genome-wide methylation profiling of ADPKD identified epigenetically regulated genes associated with renal cyst development. Human Genetics 133, 281–297.
77.Woo, YM et al. (2015) Epigenetic silencing of the MUPCDH gene as a possible prognostic biomarker for cyst growth in ADPKD. Scientific Reports 5, 15238.
78.Woo, YM et al. (2017) Profiling of miRNAs and target genes related to cystogenesis in ADPKD mouse models. Scientific Reports 7, 14151.
79.Zawia, NH, Lahiri, DK and Cardozo-Pelaez, F (2009) Epigenetics, oxidative stress, and Alzheimer disease. Free Radical Biology and Medicine 46, 1241–1249.
80.Pálmai-Pallag, T and Bachrati, CZ (2014) Inflammation-induced DNA damage and damage-induced inflammation: a vicious cycle. Microbes and Infection 16, 822–832.
81.Ta, MHT, Harris, DCH and Rangan, GK (2013) Role of interstitial inflammation in the pathogenesis of polycystic kidney disease: inflammation in polycystic kidney disease. Nephrology 18, 317–330.
82.Dmitrieva, NI, Bulavin, DV and Burg, MB (2003) High NaCl causes Mre11 to leave the nucleus, disrupting DNA damage signaling and repair. American Journal of Physiology – Renal Physiology 285, 266–274.
83.Schupp, N et al. (2007) Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. American Journal of Physiology – Renal Physiology 292, F1427–F1434.
84.Schmid, U et al. (2008) Angiotensin II induces DNA damage in the kidney. Cancer Research 68, 9239–9246.
85.Brand, S, Amann, K and Schupp, N (2013) Angiotensin II-induced hypertension dose-dependently leads to oxidative stress and DNA damage in mouse kidneys and hearts. Journal of Hypertension 31, 333–344.
86.Ma, Z et al. (2014) DNA damage response in renal ischemia-reperfusion and ATP-depletion injury of renal tubular cells. Biochimica et Biophysica Acta – Molecular Basis of Disease 1842, 1088–1096.
87.Prasad, S et al. (2009) Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury. American Journal of Pathology 175, 1493–1503.
88.Happé, H et al. (2009) Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways. Human Molecular Genetics 18, 2532–2542.
89.Alexandrov, LB et al. (2015) Clock-like mutational processes in human somatic cells. Nature Genetics 47, 1402.
90.Collins, AR (2004) The comet assay for DNA damage and repair. Molecular Biotechnology 26, 249.
91.Schupp, N, Stopper, H and Heidland, A (2016) DNA damage in chronic kidney disease: evaluation of clinical biomarkers. Oxidative Medicine and Cellular Longevity 2016, 3592042.
92.Sharma, A, Singh, K and Almasan, A (2012) Histone H2AX phosphorylation: a marker for DNA damage. In Bjergbæk, L (ed.), DNA Repair Protocols. Methods in Molecular Biology (Methods and Protocols), vol. 920. Totowa, New Jersey, USA: Humana Press, pp. 613–626.
93.Bonner, WM et al. (2008) γH2AX and cancer. Nature Reviews Cancer 8, 957–967.
94.Mah, LJ, El-Osta, A and Karagiannis, TC (2010) γh2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24, 679–686.
95.Siddiqui, MS et al. (2015) Persistent gamma H2AX: a promising molecular marker of DNA damage and aging. Mutation Research – Reviews in Mutation Research 766, 1–19.
96.Yuan, J and Chen, J (2010) MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX. Journal of Biological Chemistry 285, 1097–1104.
97.Valavanidis, A, Vlachogianni, T and Fiotakis, C (2009) 8-Hydroxy-2′-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis & Ecotoxicology Reviews 27, 120–139.
98.Cooke, MS et al. (2009) Urinary 8-oxo-2′-deoxyguanosine – source, significance and supplements. Free Radical Research 32, 381–397.
99.Pilger, A and Rüdiger, HW (2006) 8-Hydroxy-2′-deoxyguanosine as a marker of oxidative DNA damage related to occupational and environmental exposures. International Archives of Occupational and Environmental Health 80, 1–15.
100.Santella, RM (1999) Immunological methods for detection of carcinogen-DNA damage in humans. Cancer Epidemiology, Biomarkers & Prevention 8, 733–739.
101.Figueroa-Gonzalez, G and Perez-Plasencia, C (2017) Strategies for the evaluation of DNA damage and repair mechanisms in cancer. Oncology Letters 13, 3982–3988.
102.Schrier, RW et al. (2014) Blood pressure in early autosomal dominant polycystic kidney disease. The New England Journal of Medicine 371, 2255–2266.
103.Brand, S et al. (2014) Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors. PLoS One 9, e115715.
104.Torres, VE et al. (2017) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology, Dialysis, Transplantation 32, 1262–1262.
105.Torres, VE et al. (2016) Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 Trial. Clinical Journal of the American Society of Nephrology 11, 803–811.
106.Wyatt, CM and Le Meur, Y (2018) REPRISE: tolvaptan in advanced polycystic kidney disease. Kidney International 93, 292–295.
107.Nazari, A et al. (2015) Vasopressin attenuates ischemia-reperfusion injury via reduction of oxidative stress and inhibition of mitochondrial permeability transition pore opening in rat hearts. European Journal of Pharmacology 760, 96–102.
108.Xiao, L-Y and Kan, W-M (2017) Cyclic AMP (cAMP) confers drug resistance against DNA damaging agents via PKAIA in CML cells. European Journal of Pharmacology 794, 201–208.
109.Faraco, G et al. (2014) Water deprivation induces neurovascular and cognitive dysfunction through vasopressin-induced oxidative stress. Journal of Cerebral Blood Flow & Metabolism 34, 852–860.
110.Takiar, V et al. (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proceedings of the National Academy of Sciences of the United States of America 108, 2462–2467.
111.Chang, MY et al. (2017) Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency. Scientific Reports 7, 7161.
112.Ohnishi, S, Mizutani, H and Kawanishi, S (2016) The enhancement of oxidative DNA damage by anti-diabetic metformin, buformin, and phenformin, via nitrogen-centered radicals. Free Radical Research 50, 929–937.
113.Amador, RR et al. (2012) Metformin (dimethyl-biguanide) induced DNA damage in mammalian cells. Genetics and Molecular Biology 35, 153–158.
114.DeCensi, A et al. (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research 3, 1451–1461.
115.Zakikhani, M et al. (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research 66, 10269–10273.
116.Dowling, RJO et al. (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research 67, 10804–10812.
117.Buzzai, M et al. (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Research 67, 6745–6752.
118.Zakikhani, M et al. (2008) The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prevention Research 1, 369–375.
119.Othman, EM et al. (2016) Metformin protects kidney cells from insulin-mediated genotoxicity in vitro and in male Zucker diabetic fatty rats. Endocrinology 157, 548–559.
120.Najafi, M et al. (2018) Metformin: prevention of genomic instability and cancer: a review. Mutation Research – Genetic Toxicology and Environmental Mutagenesis 827, 1–8.
121.Zhou, X et al. (2013) Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. Journal of Clinical Investigation 123, 3084–3098.
122.Surjana, D, Halliday, GM and Damian, DL (2010) Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. Journal of Nucleic Acids 2010, 157591.
123.Chen, AC et al. (2015) A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. The New England Journal of Medicine 373, 1618–1626.
124.Leonhard, WN et al. (2011) Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. American Journal of Physiology – Renal Physiology 300, 1193–1202.
125.Shang, H-S et al. (2016) Curcumin causes DNA damage and affects associated protein expression in HeLa human cervical cancer cells. Oncology Reports 36, 2207–2215.
126.Cao, J et al. (2006) Mitochondrial and nuclear DNA damage induced by curcumin in human hepatoma G2 cells. Toxicological Sciences 91, 476–483.
127.Ting, C-Y et al. (2015) Curcumin triggers DNA damage and inhibits expression of DNA repair proteins in human lung cancer cells. Anticancer Research 35, 3867–3874.
128.Chen, X et al. (2017) Curcumin activates DNA repair pathway in bone marrow to improve carboplatin-induced myelosuppression. Scientific Reports 7, 17724–17711.
129.Natoli, TA et al. (2010) Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nature Medicine 16, 788–792.
130.Torres, VE et al. (2011) Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology 6, 640–647.
131.Torres, VE et al. (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney International 91, 493–500.
132.Amro, OWMDMS et al. (2016) Low-Osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial. American Journal of Kidney Diseases 68, 882–891.
133.Warner, G et al. (2016) Food restriction ameliorates the development of polycystic kidney disease. Journal of the American Society of Nephrology 27, 1437–1447.
134.Kipp, KR et al. (2016) A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. American Journal of Physiology – Renal Physiology 310, F726–F731.
135.Nowak, KL et al. (2017) Overweight and obesity Are predictors of progression in early autosomal dominant polycystic kidney disease. Journal of the American Society of Nephrology 29, 571–578.
136.Haley-Zitlin, V and Richardson, A (1993) Effect of dietary restriction on DNA repair and DNA damage. Mutation Research DNAging 295, 237–245.
137.Heydari, AR et al. (2007) Caloric restriction and genomic stability. Nucleic Acids Research 35, 7485–7496.
138.Subba Rao, K (2003) Dietary calorie restriction, DNA-repair and brain aging. Molecular and Cellular Biochemistry 253, 313–318.
139.Vermeij, WP et al. (2016) Restricted diet delays accelerated ageing and genomic stress in DNA-repair-deficient mice. Nature 537, 427–431.
140.Seliger, SL et al. (2018) A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease. American Journal of Nephrology 47, 352–360.
141.Lu, H-F et al. (2009) Curcumin-induced DNA damage and inhibited DNA repair genes expressions in mouse-rat hybrid retina neuroblastoma cells ganglion cells (n18). Neurochemical Research 34, 1491–1497.
142.Shayman, JA (2016) Targeting glycosphingolipid metabolism to treat kidney disease. Nephron 134, 37–42.
143.Shayman, JA (2018) Targeting glucosylceramide synthesis in the treatment of rare and common renal disease. Seminars in Nephrology 38, 183–192.
144.Deshmukh, GD et al. (1994) Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (cpk/cpk) mouse. Journal of Lipid Research 35, 1611–1618.
145.Chatterjee, S et al. (1996) Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. Journal of Lipid Research 37, 1334–1344.
146.Carroll, B, Donaldson, JC and Obeid, L (2015) Sphingolipids in the DNA damage response. Advances in Biological Regulation 58, 38–52.
147.Vit, J-P and Rosselli, F (2003) Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis. Oncogene 22, 8645–8652.
148.Couto, D et al. (2016) New insights on non-enzymatic oxidation of ganglioside GM1 using mass spectrometry. Journal of the American Society for Mass Spectrometry 27, 1965–1978.
149.Couto, D et al. (2015) Glycosphingolipids and oxidative stress: evaluation of hydroxyl radical oxidation of galactosyl and lactosylceramides using mass spectrometry. Chemistry and Physics of Lipids 191, 106–114.
150.Menezes, LF and Germino, GG (2015) Systems biology of polycystic kidney disease: a critical review. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 7, 39–52.